CY1114912T1 - Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου - Google Patents

Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου

Info

Publication number
CY1114912T1
CY1114912T1 CY20141100076T CY141100076T CY1114912T1 CY 1114912 T1 CY1114912 T1 CY 1114912T1 CY 20141100076 T CY20141100076 T CY 20141100076T CY 141100076 T CY141100076 T CY 141100076T CY 1114912 T1 CY1114912 T1 CY 1114912T1
Authority
CY
Cyprus
Prior art keywords
vaccine
methods
breast cancer
inducing
patient
Prior art date
Application number
CY20141100076T
Other languages
English (en)
Inventor
George E Peoples
Ponniah Sathibalan
Original Assignee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. filed Critical The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Publication of CY1114912T1 publication Critical patent/CY1114912T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/38Antigens from snakes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403Receptors for growth factors
    • A61K39/464406Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η εφεύρεση παρουσιάζει μεθόδους για επαγωγή και διατήρηση μιας προστατευτικής απόκρισης Τ λεμφοκυττάρων σε ένα πεπτίδιο του HER/neu ογκογονιδίου, το Ε75, με το αποτέλεσμα της επαγωγής και διατήρησης προστατευτικής ή θεραπευτικής ανοσίας έναντι του καρκίνου του μαστού σε έναν ασθενή σε κλινική ύφεση. Οι μέθοδοι περιλαμβάνουν χορήγηση στον ασθενή μιας αποτελεσματικής ποσότητας μιας σύνθεσης εμβολίου που περιλαμβάνει έναν φαρμακευτικά αποδεκτό φορέα, ένα ανοσοενισχυτικό όπως ανασυνδυασμένο ανθρώπινο GM-CSF και το Ε75 πεπτίδιο σε μία βελτιστοποιημένη δόση και χρονοδιάγραμμα. Οι μέθοδοι περαιτέρω περιλαμβάνουν χορήγηση μιας ετήσιας ή ημι-ετήσιας δόσης αναμνηστικού εμβολίου λόγω της μειούμενης ειδικής για Ε75 Τ κυττάρων ανοσίας. Η εφεύρεση επίσης παρουσιάζει συνθέσεις εμβολίου για χρήση στις μεθόδους.
CY20141100076T 2007-06-01 2014-01-30 Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου CY1114912T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94152407P 2007-06-01 2007-06-01
EP08745615.8A EP2162149B1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Publications (1)

Publication Number Publication Date
CY1114912T1 true CY1114912T1 (el) 2017-01-25

Family

ID=40094045

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100076T CY1114912T1 (el) 2007-06-01 2014-01-30 Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου

Country Status (16)

Country Link
US (6) US8222214B2 (el)
EP (2) EP2162149B1 (el)
JP (6) JP5635399B2 (el)
KR (5) KR101863534B1 (el)
CN (2) CN105816867A (el)
AU (1) AU2008260399C1 (el)
CA (1) CA2687368C (el)
CY (1) CY1114912T1 (el)
DK (1) DK2162149T3 (el)
ES (1) ES2445399T3 (el)
HR (1) HRP20140102T1 (el)
MX (1) MX2009012858A (el)
PL (1) PL2162149T3 (el)
PT (1) PT2162149E (el)
SI (1) SI2162149T1 (el)
WO (1) WO2008150577A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
SI2162149T1 (sl) * 2007-06-01 2014-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cepivo za preprečevanje relapsa raka na dojki
BRPI0922849B1 (pt) 2008-12-10 2023-01-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Composição de vacina com uma quantidade eficaz de um peptídeo gp2 e de gm-csf
WO2013123424A1 (en) 2012-02-17 2013-08-22 Mayo Foundation For Medical Education And Research Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide
US10028918B2 (en) 2012-05-08 2018-07-24 Albert Einstein College Of Medicine, Inc. Nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine and uses thereof
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
KR20140100418A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 점막 투여용 백신 조성물
IN2014CH00390A (el) * 2013-02-05 2015-07-31 Nitto Denko Corp
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015066020A1 (en) * 2013-10-28 2015-05-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of monitoring immune responses
US10434152B2 (en) * 2014-02-20 2019-10-08 Wayne State University HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
EA037855B1 (ru) 2016-01-29 2021-05-27 Сорренто Терапьютикс, Инк. Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1
MA45169A (fr) 2016-05-31 2019-04-10 Sellas Life Sciences Group Inc Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
WO2020086412A1 (en) * 2018-10-21 2020-04-30 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
CN117280219A (zh) 2021-05-04 2023-12-22 阿斯顿科学公司 Her2疫苗组合物
KR20230017640A (ko) 2021-07-28 2023-02-06 주식회사 애스톤사이언스 Her2 백신 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech Inc Her2 extrazellulare domäne
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0793501A4 (en) * 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US20030022820A1 (en) * 1995-12-14 2003-01-30 Linda A. Sherman In vivo activation of tumor-specific cytotoxic t cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
WO2001008636A2 (en) * 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US20030028907A1 (en) * 2001-07-03 2003-02-06 Walke D. Wade Novel human kielin-like proteins and polynucleotides encoding the same
CA2386032A1 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
AU2002354644C1 (en) * 2001-07-10 2009-04-30 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
AU2003230603A1 (en) 2002-03-08 2003-09-22 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Her-2/neu DNA 백신
DK1553966T3 (da) * 2002-10-03 2012-09-17 Wyeth Corp Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf
WO2004069866A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
EP1635766A4 (en) * 2003-06-06 2009-09-30 Agennix Inc LACTOFERRIN AS ADJUVANS IN CANCER VACCINES
WO2005014634A1 (en) * 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
SI2162149T1 (sl) * 2007-06-01 2014-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cepivo za preprečevanje relapsa raka na dojki

Also Published As

Publication number Publication date
CA2687368C (en) 2018-10-30
KR101863534B1 (ko) 2018-06-04
KR20180061412A (ko) 2018-06-07
KR20150106870A (ko) 2015-09-22
WO2008150577A1 (en) 2008-12-11
CA2687368A1 (en) 2008-12-11
US20190060429A1 (en) 2019-02-28
US20220241389A1 (en) 2022-08-04
AU2008260399A8 (en) 2010-01-07
US9370560B2 (en) 2016-06-21
KR102079921B1 (ko) 2020-02-21
JP2017071607A (ja) 2017-04-13
US10842856B2 (en) 2020-11-24
AU2008260399C1 (en) 2014-07-17
CN105816867A (zh) 2016-08-03
EP2722336A1 (en) 2014-04-23
US20100209443A1 (en) 2010-08-19
US8222214B2 (en) 2012-07-17
ES2445399T3 (es) 2014-03-03
US8796220B2 (en) 2014-08-05
PL2162149T3 (pl) 2014-04-30
HRP20140102T1 (hr) 2014-03-28
DK2162149T3 (da) 2014-02-10
KR101572474B1 (ko) 2015-11-30
JP2010529026A (ja) 2010-08-26
JP5635399B2 (ja) 2014-12-03
EP2162149A4 (en) 2012-07-25
KR20210097209A (ko) 2021-08-06
PT2162149E (pt) 2014-02-12
AU2008260399A1 (en) 2008-12-11
KR20100027187A (ko) 2010-03-10
EP2162149A1 (en) 2010-03-17
CN101678093A (zh) 2010-03-24
SI2162149T1 (sl) 2014-04-30
US20220347281A1 (en) 2022-11-03
JP2022095926A (ja) 2022-06-28
JP7072467B2 (ja) 2022-05-20
JP6097724B2 (ja) 2017-03-15
US20150182609A1 (en) 2015-07-02
JP2018199691A (ja) 2018-12-20
AU2008260399B2 (en) 2014-01-16
MX2009012858A (es) 2010-02-03
KR20200019776A (ko) 2020-02-24
EP2162149B1 (en) 2013-11-06
JP2021001218A (ja) 2021-01-07
US20130189290A1 (en) 2013-07-25
JP2014237653A (ja) 2014-12-18
KR102283639B1 (ko) 2021-08-02

Similar Documents

Publication Publication Date Title
CY1114912T1 (el) Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου
Zitvogel et al. Immunological off-target effects of imatinib
Slingluff Jr et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine
Abu Eid et al. Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition
BR112021024966A2 (pt) Composições e métodos para administração subcutânea de imunoterapia de câncer
CY1121258T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
Wachowska et al. 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy
BR112016000810A2 (pt) imunoterapia contra vários tumores tais como câncer de pulmão, incluindo cpcnp
ATE522600T1 (de) Anti-tumor impfstoff aus normalen chemisch modifizierten cd4+ zellen
MX353165B (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
BR112016025035A2 (pt) imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml)
BRPI0510430A (pt) composições e métodos para vacinação mucosal
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
MY162741A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin D1
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
BRPI0408774A (pt) vacinas de dna contra crescimento tumoral e seus usos
MX2010002002A (es) Peptido foxm1 y agente medicinal que lo contiene.
CY1124812T1 (el) Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου
BRPI0820960B8 (pt) composição, composição farmacêutica, e uso da composição
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
BR112013001946A2 (pt) vírus varicela zoster inativado, composição farmacêutica, método para preparar um vírus varicela zoster inativado, vacina, e, método para o tratamento de herpes zoster em um indivíduo
BR112013028285A2 (pt) indução de il-12 usando imunoterapia
BR112015004349A2 (pt) peptídeos de ube2t e vacinas contendo os mesmos